Colchicine May Benefit Patients With Diabetes and Recent MI

After an MI, patients with vs without T2D have a higher risk for another cardiovascular event.
The Cochicine Cardiovascular Outcomes Trial (COLCOT), a randomized, double-blinded trial, found a lower risk for ischemic cardiovascular events with 0.5 mg colchicine taken daily vs placebo, initiated within 30 days of an MI.
Researchers conducted a prespecified subgroup analysis of 959 adult patients with T2D (mean age, 62.4 years; 22.2% women) in COLCOT (462 patients in colchicine and 497 patients in placebo groups).
The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization within a median 23 months.
The patients were taking a variety of appropriate medications, including aspirin and another antiplatelet agent and a statin (98%-99%) and metformin (75%-76%).

The risk for the primary endpoint was reduced by 35% in patients with T2D who received colchicine than in those who received placebo (hazard ratio, 0.65; P = .03).
The primary endpoint event rate per 100 patient-months was significantly lower in the colchicine group than in the placebo group (rate ratio, 0.53; P = .01).
The frequencies of adverse events were similar in both the treatment and placebo groups (14.6% and 12.8%, respectively; P = .41), with gastrointestinal adverse events being the most common.
In COLCOT, patients with T2D had a 1.86-fold higher risk for a primary endpoint cardiovascular event, but there was no significant difference in the primary endpoint between those with and without T2D on colchicine.

Patients with both T2D and a recent MI derive a large benefit from inflammation-reducing therapy with colchicine.

Non-cardiac birth defects and long-term risk of cardiovascular hospitalisation Patients with heart defects are at risk of developing cardiovascular disease. Our objective was to determine if non-cardiac birth defects are associated with the risk of cardiovascular hospitalisation.

Urate in Atherosclerotic Plaques Boosts Risk for CV Events Patients with gout and hyperuricemia harboring cardiovascular (CV) monosodium urate (MSU) deposits in atherosclerotic plaques are at an increased risk for major adverse cardiovascular events (MACE).

Don't Overlook Underlying CV Risks In RA Treatmen Patients with rheumatoid arthritis (RA) carry a high risk for cardiovascular events, but mounting clinical evidence suggests they're being undertreated to manage that risk. Rheumatologists should consider a patient with RA's cardiovascular disease (CVD) status before deciding on RA treatments, a researcher of cardiometabolic disorders advised.

Microvascular disease and arrhythmias: a renewed focus on the myocardial microvasculature? Arrhythmias, and in particular atrial fibrillation (AF), are one of the greatest healthcare challenges of our time. Hospitalisation due to this condition is exponentially growing, and now outnumbers those for both heart failure and myocardial infarction.

In Angina, Gene Therapy Coaxes Heart Vessel Growth An experimental new gene therapy has specialists questioning whether heart vessel growth to restore blood flow could actually be possible in refractory angina after bypass surgery.

CARDIOPROGRESS
Foundation for the advancement of cardiology